{"id":"NCT02289963","sponsor":"Sanofi","briefTitle":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2016-04","completion":"2016-04","firstPosted":"2014-11-13","resultsPosted":"2017-06-26","lastUpdate":"2017-06-26"},"enrollment":199,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Placebo (for Alirocumab)","otherNames":[]},{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553","REGN727","PraluentÂ®"]},{"type":"DRUG","name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT) in comparison with placebo after 24 weeks of treatment in high cardiovascular risk participants with hypercholesterolemia in South Korea and Taiwan.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab in comparison with placebo on LDL-C after 12 weeks of treatment.\n* To evaluate the effect of alirocumab on other lipid parameters: apolipoprotein B (Apo B), non high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), lipoprotein (a) (Lp \\[a\\]), high-density lipoprotein cholesterol (HDL-C), triglycerides (TGs), and apolipoprotein A-1 (Apo A-1).\n* To evaluate the safety and tolerability of alirocumab.\n* To evaluate the development of anti-alirocumab antibodies (ADA).","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Placebo Q2W","deltaMin":6.3,"sd":2.9},{"arm":"Alirocumab 75 mg Q2W/Up to 150 mg Q2W","deltaMin":-57.1,"sd":3}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":9},"locations":{"siteCount":27,"countries":["South Korea","Taiwan"]},"refs":{"pmids":["33078867","30946207","29153823"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":102},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Dizziness","Headache","Diarrhoea"]}}